Home › Linfoma di Burkitt › Washington
Studi clinici su Linfoma di Burkitt nello stato di Washington
11 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Washington.
Città nello stato di Washington
Testo ufficiale dello studio (inglese)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- e altri 1
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2Volontari sani benvenuti
6 Months · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 apr 2026 · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 nov 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 nov 2024 · NCT06034275Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.